InMed Pharmaceuticals Nasdaq/NYSE Compliance Notice
InMed Pharmaceuticals received a deficiency notice from Nasdaq for failing to maintain the minimum $2.5 million shareholders' equity requirement for continued listing. The company reported shareholders' equity of $1,075,007, largely due to expenses related to its pending merger with Mentari Therapeutics. InMed expects to regain compliance upon the closing of the merger, which is anticipated to bring approximately $490 million in gross proceeds to the combined company.
- Counterparty
- The Nasdaq Stock Market LLC
- Term
- 45 days to submit plan